Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

BACKGROUND: Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. METHODS: In a phase 3 trial, we r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Shanafelt, Tait D., Wang, Xin V., Kay, Neil E., Hanson, Curtis A., O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F., Braggio, Esteban, Leis, Jose F., Zhang, Cong C., Coutre, Steven E., Barr, Paul M., Cashen, Amanda F., Mato, Anthony R., Singh, Avina K., Mullane, Michael P., Little, Richard F., Erba, Harry, Stone, Richard M., Litzow, Mark, Tallman, Martin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6908306/
https://ncbi.nlm.nih.gov/pubmed/31365801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1817073
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller